Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib
Authors:
- Katsuyuki KiuraKKKatsuyuki Kiura
- Shinichi ToyookaSTShinichi Toyooka
- Katsuyuki HottaKHKatsuyuki Hotta
- Masahiro TabataMTMasahiro Tabata
- Nagio TakigawaNTNagio Takigawa
- Junichi SohJSJunichi Soh
- Yasushi TanimotoYTYasushi Tanimoto
- Arihiko KanehiroAKArihiko Kanehiro
- Katsuya KatoKKKatsuya Kato
- Hiroshi DateHDHiroshi Date
- Mitsune TanimotoMTMitsune Tanimoto
- 31 January 2008
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 59 (1) , 81-87
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Circulating KL‐6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinomaInternational Journal of Cancer, 2007
- Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clampBritish Journal of Cancer, 2006
- Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene MutationsJournal of Clinical Oncology, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experienceAnnals of Oncology, 2005
- P-485 EGFR mutations do not accurately predict response to erlotinib in first-line monotherapy treatment of advanced non-small-cell lung cancerLung Cancer, 2005
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLOS Medicine, 2005
- Detection of serum and intrahepatic KL-6 in anti-HCV positive patients with hepatocellular carcinomaHepatology Research, 2004
- MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients.Journal of Clinical Pathology, 1998